Search

Displaying results 2591 - 2600 of 4539 in total
  1. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. … emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by

  2. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. It is a small molecule designed to act as a pharmacological chaperone that specifically b...

  3. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    An IND for XL019 was filed by Exelixis in May 2007.

  4. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

    Mixtures: PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETLI), PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETSIZ)
  5. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    ” status by the U.S. … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.

  6. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. … Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.

  7. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    by sulphate. … Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS) and

  8. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

  9. Drug

    Tertomotide

    go.drugbank.com/drugs/DB12747
    Investigational

    It is being developed by Pharmexa A/S.

  10. Drug

    19-norandrostenedione

    go.drugbank.com/drugs/DB01434
    ExperimentalIllicit

    19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. … After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.